Singular Genomics Systems Stock Performance
| OMIC Stock | USD 20.01 0.00 0.00% |
The entity has a beta of 0.0772, which indicates not very significant fluctuations relative to the market. As returns on the market increase, Singular Genomics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Singular Genomics is expected to be smaller as well. At this point, Singular Genomics Systems has a negative expected return of -0.13%. Please make sure to validate Singular Genomics' value at risk, as well as the relationship between the kurtosis and day typical price , to decide if Singular Genomics Systems performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Singular Genomics Systems has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest weak performance, the Stock's forward indicators remain sound and the latest tumult on Wall Street may also be a sign of longer-term gains for the firm shareholders. ...more
Actual Historical Performance (%)
Year To Date Return 2.09 | Ten Year Return (97.41) | All Time Return (97.41) |
Last Split Factor 1:30 | Last Split Date 2024-06-26 |
1 | Disposition of 250 shares by Eli Glezer of Singular Genomics subject to Rule 16b-3 | 11/26/2024 |
2 | Acquisition by Andrew Spaventa of 915000 shares of Singular Genomics subject to Rule 16b-3 | 12/06/2024 |
3 | Disposition of 306 shares by Andrew Spaventa of Singular Genomics subject to Rule 16b-3 | 12/16/2024 |
4 | Singular Genomics Enters into Agreement to be Acquired by Deerfield for 20.00 in Cash per Share | 12/23/2024 |
5 | Acquisition by Jyotsna Ghai of 417 shares of Singular Genomics subject to Rule 16b-3 | 01/02/2025 |
6 | OMIC Investors Have the Opportunity to Join Investigation of Singular Genomics Systems, Inc. with the Schall Law Firm | 01/17/2025 |
7 | Long Term Investment Analysis - Stock Traders Daily | 01/30/2025 |
8 | Disposition of 250 shares by Jyotsna Ghai of Singular Genomics subject to Rule 16b-3 | 02/07/2025 |
9 | Acquisition by Andrew Spaventa of 1907 shares of Singular Genomics subject to Rule 16b-3 | 02/12/2025 |
10 | Disposition of 1107 shares by Andrew Spaventa of Singular Genomics subject to Rule 16b-3 | 02/14/2025 |
11 | Singular Genomics Systems Reports Results of Special Stockholder Meeting | 02/21/2025 |
| Begin Period Cash Flow | 76 M | |
| Free Cash Flow | -74.6 M |
Singular |
Singular Genomics Relative Risk vs. Return Landscape
If you would invest 2,171 in Singular Genomics Systems on December 1, 2024 and sell it today you would lose (170.00) from holding Singular Genomics Systems or give up 7.83% of portfolio value over 90 days. Singular Genomics Systems is currently does not generate positive expected returns and assumes 1.6452% risk (volatility on return distribution) over the 90 days horizon. In different words, 14% of stocks are less volatile than Singular, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Singular Genomics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Singular Genomics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Singular Genomics Systems, and traders can use it to determine the average amount a Singular Genomics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0801
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | OMIC |
Estimated Market Risk
| 1.65 actual daily | 14 86% of assets are more volatile |
Expected Return
| -0.13 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.08 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Singular Genomics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Singular Genomics by adding Singular Genomics to a well-diversified portfolio.
Singular Genomics Fundamentals Growth
Singular Stock prices reflect investors' perceptions of the future prospects and financial health of Singular Genomics, and Singular Genomics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Singular Stock performance.
| Return On Equity | -0.54 | ||||
| Return On Asset | -0.24 | ||||
| Operating Margin | (44.51) % | ||||
| Current Valuation | (12.58 M) | ||||
| Shares Outstanding | 2.54 M | ||||
| Price To Earning | 35.71 X | ||||
| Price To Book | 0.41 X | ||||
| Price To Sales | 19.03 X | ||||
| Revenue | 2.91 M | ||||
| Gross Profit | (1.35 M) | ||||
| EBITDA | (86.5 M) | ||||
| Net Income | (94.82 M) | ||||
| Cash And Equivalents | 287.98 M | ||||
| Cash Per Share | 4.05 X | ||||
| Total Debt | 75.29 M | ||||
| Debt To Equity | 0.20 % | ||||
| Current Ratio | 22.98 X | ||||
| Book Value Per Share | 49.16 X | ||||
| Cash Flow From Operations | (73.65 M) | ||||
| Earnings Per Share | (34.68) X | ||||
| Market Capitalization | 50.77 M | ||||
| Total Asset | 265.47 M | ||||
| Retained Earnings | (337.6 M) | ||||
| Working Capital | 173.94 M | ||||
About Singular Genomics Performance
By analyzing Singular Genomics' fundamental ratios, stakeholders can gain valuable insights into Singular Genomics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Singular Genomics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Singular Genomics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 1.3 K | 2.2 K | |
| Return On Tangible Assets | (0.32) | (0.34) | |
| Return On Capital Employed | (0.37) | (0.39) | |
| Return On Assets | (0.32) | (0.34) | |
| Return On Equity | (0.61) | (0.58) |
Things to note about Singular Genomics Systems performance evaluation
Checking the ongoing alerts about Singular Genomics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Singular Genomics Systems help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Singular Genomics generated a negative expected return over the last 90 days | |
| Singular Genomics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 2.91 M. Net Loss for the year was (94.82 M) with loss before overhead, payroll, taxes, and interest of (1.35 M). | |
| Singular Genomics Systems currently holds about 287.98 M in cash with (73.65 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.05. | |
| Singular Genomics has a frail financial position based on the latest SEC disclosures | |
| Roughly 14.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from thelincolnianonline.com: Singular Genomics Systems Reports Results of Special Stockholder Meeting |
- Analyzing Singular Genomics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Singular Genomics' stock is overvalued or undervalued compared to its peers.
- Examining Singular Genomics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Singular Genomics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Singular Genomics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Singular Genomics' stock. These opinions can provide insight into Singular Genomics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Singular Stock analysis
When running Singular Genomics' price analysis, check to measure Singular Genomics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Singular Genomics is operating at the current time. Most of Singular Genomics' value examination focuses on studying past and present price action to predict the probability of Singular Genomics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Singular Genomics' price. Additionally, you may evaluate how the addition of Singular Genomics to your portfolios can decrease your overall portfolio volatility.
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance |